| Followers | 12 |
| Posts | 969 |
| Boards Moderated | 0 |
| Alias Born | 04/02/2018 |
Sunday, June 18, 2023 11:37:16 AM
Yes, it is:
https://alz-journals.onlinelibrary.wiley.com/hub/journal/15525279/homepage/author-guidelines#AFTERSUBMISSION
AFTER SUBMISSION
Articles are first evaluated by senior editors for suitability for the journal. The goal of this initial evaluation is to provide authors with a quick decision so that if the article is not likely to review well, does not provide novel insights, or does not represent a significant impact, authors are notified so that they can submit elsewhere.
Articles that may be more appropriate for one of the companion journals (A&D DADM or A&D TRCI) are shared with their editors and if their editors are interested in the article a recommendation for transfer is made to the authors.
Articles that meet the initial review by editors are handled by the appropriate section editor. The section editor will solicit a minimum of two independent reviews. At their discretion, editors can solicit more reviews should they feel they are needed. Reviewers can make a recommendation of minor revision, major revision, reject, or accept. Reviewers also provide an impact score from 0-100. The section editor will evaluate the independent reviews and provide a decision recommendation to the editor-in-chief and/or deputy editor if the editor-in-chief is in conflict.
https://alz-journals.onlinelibrary.wiley.com/hub/journal/15525279/homepage/author-guidelines#AFTERSUBMISSION
AFTER SUBMISSION
Articles are first evaluated by senior editors for suitability for the journal. The goal of this initial evaluation is to provide authors with a quick decision so that if the article is not likely to review well, does not provide novel insights, or does not represent a significant impact, authors are notified so that they can submit elsewhere.
Articles that may be more appropriate for one of the companion journals (A&D DADM or A&D TRCI) are shared with their editors and if their editors are interested in the article a recommendation for transfer is made to the authors.
Articles that meet the initial review by editors are handled by the appropriate section editor. The section editor will solicit a minimum of two independent reviews. At their discretion, editors can solicit more reviews should they feel they are needed. Reviewers can make a recommendation of minor revision, major revision, reject, or accept. Reviewers also provide an impact score from 0-100. The section editor will evaluate the independent reviews and provide a decision recommendation to the editor-in-chief and/or deputy editor if the editor-in-chief is in conflict.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
